Novartis | NOVN - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Alcon AG USD 31.62B 64M 2026-03
Almirall EUR 2.37B 29.97M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Autolus Therapeutics Ltd USD 493.23M 33.84M 2026-06
Bayer EUR 107.29B 659M 2026-06
Biogen USD 32.09B 2.6B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Fresenius EUR 41.84B 526M 2026-06
Fresenius Medical Care EUR 31.29B 174.35M 2026-06
Genmab DKK 12.52B 139M 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
GRIFOLS EUR 20.09B 12M 2026-06
Hikma Pharmaceutical USD 5.67B 117M 2025-12
J&J USD 201.06B 167M 2026-06
Lakefront Biotherapeutics EUR 3.37B 34.09M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck EUR 52.69B 383M 2026-06
Merck USD 129.8B 1.12B 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Novo Nordisk DKK 594.94B 35.72B 2026-06
Orion EUR 1.87B 205.5M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Philips EUR 26.7B 565M 2026-06
Recordati EUR 5.37B 33.76M 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
UCB EUR 18.16B 971M 2025-12